{"id":123960,"date":"2025-09-06T20:43:18","date_gmt":"2025-09-06T20:43:18","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/123960\/"},"modified":"2025-09-06T20:43:18","modified_gmt":"2025-09-06T20:43:18","slug":"abington-neurological-associates-administered-pas-first-infusion-of-an-alzheimers-medication-in-2023-the-treatment-is-now-available-in-a-self-injecting-pen","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/123960\/","title":{"rendered":"Abington Neurological Associates administered PA&#8217;s first infusion of an Alzheimer&#8217;s medication in 2023. The treatment is now available in a self-injecting pen"},"content":{"rendered":"<p>Leqembi, the first medication to treat the memory disorder, is now available in a self-injecting pen, TIME Magazine <a href=\"https:\/\/time.com\/7314266\/alzheimers-drug-injectable-leqembi\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">reported<\/a>.<\/p>\n<p>Described as \u201cthe first at-home treatment for Alzheimer\u2019s\u201d, the drug was approved by the U.S. Food and Drug Administration (FDA) in 2023.<\/p>\n<p>From TIME\u2019s coverage:<\/p>\n<p>The self-injectable version works in a similar way to the auto-injector pens that deliver weight-loss drugs like\u00a0<a href=\"https:\/\/time.com\/7284750\/weight-loss-drug-wegovy-zepbound\/\" rel=\"nofollow noopener\" target=\"_blank\">Wegovy and Zepbound<\/a>, and could make the Alzheimer\u2019s drug accessible to more people. In January 2025, the FDA approved lecanemab for\u00a0<a href=\"https:\/\/www.eisai.com\/news\/2025\/news202506.html\" rel=\"nofollow noopener\" target=\"_blank\">maintenance therapy<\/a>, but patients still had to get the drug via infusion at infusion centers. Now, Iqlik will give people more flexibility to continue their treatment. Once they complete the initial treatment regimen over 18 months with the IV version of lecanemab, they can either continue to get an IV infusion of the maintenance dose or give themselves an injection\u2014or switch back and forth, says Kramer.\u00a0<\/p>\n<p>For patients without insurance, the cost for a year\u2019s supply of Iqlik will be $19,500 according to Eisai, compared to $13,316 for a year of the IV maintenance therapy. Medicare currently covers lecanemab if doctors enroll patients in a registry, and costs for those with Medicare Part D are capped at $2,000 annually.<\/p>\n<p>Abington Neurological Associates (ANA), located at 1151 Old York Road, was a participating clinical trial site that contributed to the research and was involved in administering the first Leqembi infusions in Pennsylvania after its approval, according to a 2023 <a href=\"https:\/\/www.abingtonneurology.com\/news\/leqembi-infusions-begin-in-pa\/#:~:text=Abington%20Neurological%20Associates%20(ANA)%20is,70%25%20with%20drugs%20in%20development.\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">press release<\/a>.\u00a0<\/p>\n<p>ANA said they have treated over 100 patients with the medication to date.\u00a0<\/p>\n<p>For all the latest news, follow us on\u00a0<a href=\"https:\/\/www.facebook.com\/glensidelocal\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Facebook<\/a>\u00a0or sign up for Glenside Local\u2019s \u201cDaily Buzz\u201d newsletter\u00a0<a href=\"https:\/\/glensidelocal.com\/subscribe\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">here<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Leqembi, the first medication to treat the memory disorder, is now available in a self-injecting pen, TIME Magazine&hellip;\n","protected":false},"author":2,"featured_media":123961,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[64,63,137,490],"class_list":{"0":"post-123960","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-au","9":"tag-australia","10":"tag-health","11":"tag-medication"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/123960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=123960"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/123960\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/123961"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=123960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=123960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=123960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}